World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Review Article

ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 6
Page: 677-681

NOVEL BILAYER DRUG DELIVERY SYSTEM FOR IMPROVED THERAPEUTIC MANAGEMENT OF ASTHMA

Manju, Deepak Saini*, Sunita Rani

Smt. Tarawati Institute of Biomedical & Allied Sciences, Roorkee, Uttarakhand-247667.

Article Received: 15 April 2026 | | ***Article Revised: 05 May 2026*** | | ***Article Accepted: 26 May 2026***

***Corresponding Author: Deepak Saini**
Smt. Tarawati Institute of Biomedical & Allied Sciences, Roorkee, Uttarakhand-247667.
DOI: https://doi.org/10.5281/zenodo.20446418

How to cite this Article: Manju, Deepak Saini, Sunita Rani (2026) NOVEL BILAYER DRUG DELIVERY SYSTEM FOR IMPROVED THERAPEUTIC MANAGEMENT OF ASTHMA. World Journal of Pharmaceutical Science and Research, 5(6), 677-680.

ABSTRACT

Asthma is a chronic inflammatory respiratory disorder characterized by airway hyperresponsiveness, bronchoconstriction, and mucus overproduction. Despite the availability of various pharmacological treatments, effective disease management remains a challenge due to poor patient compliance, frequent dosing requirements, and limitations of conventional dosage forms. Novel drug delivery systems have emerged as promising strategies to enhance therapeutic efficacy and improve patient adherence. Among these, bilayer drug delivery systems have gained considerable attention due to their ability to provide immediate as well as sustained drug release in a single dosage form. This review highlights the design, formulation strategies, and therapeutic evaluation of bilayer drug delivery systems for asthma management. It discusses the pathophysiology of asthma, limitations of current therapies, advantages of bilayer systems, formulation approaches, evaluation techniques, and future perspectives. The integration of advanced drug delivery technologies is emphasized to achieve improved therapeutic outcomes in asthma treatment.

KEYWORDS: Bilayer tablets; Asthma; Drug delivery system; Sustained release; Immediate release; Therapeutic evaluation.

1. INTRODUCTION

Asthma is a chronic respiratory disease affecting millions of individuals worldwide and is characterized by reversible airway obstruction, inflammation, and bronchial hyper responsiveness. The disease burden continues to rise due to environmental pollution, allergens, and lifestyle changes. Conventional asthma therapies primarily include bronchodilators and corticosteroids, which provide symptomatic relief but often require frequent dosing and may cause systemic side effects.[1-3]

The need for improved therapeutic strategies has led to the development of advanced drug delivery systems that enhance drug efficacy and patient compliance. Bilayer drug delivery systems represent one such innovation, allowing the incorporation of two drugs or two release profiles within a single dosage form. These systems are particularly beneficial in asthma management, where rapid onset of action and prolonged therapeutic effect are both required.[4-6]

2. Pathophysiology of Asthma

Asthma is a complex inflammatory disorder involving multiple cellular and molecular mechanisms. The disease is characterized by chronic inflammation of the airways, mediated by immune cells such as eosinophils, mast cells, and T-helper type 2 (Th2) lymphocytes. These cells release inflammatory mediators including cytokines, leukotrienes, and histamines, which contribute to airway narrowing and mucus secretion.[7-9]

Bronchoconstriction occurs due to contraction of airway smooth muscles, leading to symptoms such as wheezing, shortness of breath, and coughing. Additionally, airway remodeling involving structural changes such as fibrosis and smooth muscle hypertrophy contributes to disease progression.[10-11] Understanding these mechanisms is crucial for designing effective drug delivery systems.

3. Current Pharmacotherapy and Limitations

Current asthma treatment includes short-acting β_2-agonists (SABAs), long-acting β_2-agonists (LABAs), corticosteroids, and leukotriene modifiers. While these therapies are effective, they suffer from several limitations such as poor patient compliance, frequent dosing, and systemic side effects.[12-13]

Inhalation therapy is the most common route of administration; however, it requires proper technique and may lead to inconsistent drug delivery. Oral formulations, on the other hand, may result in delayed onset of action and reduced bioavailability due to first-pass metabolism.[14-15] These challenges highlight the need for novel drug delivery systems.

4. Concept of Bilayer Drug Delivery System

Bilayer drug delivery systems consist of two layers: one designed for immediate release and the other for sustained or controlled release. This dual-release mechanism allows for rapid onset of action followed by prolonged therapeutic effect.[16-17]

These systems can incorporate either a single drug with different release profiles or two different drugs with complementary actions. The bilayer design helps in improving patient compliance by reducing dosing frequency and enhancing therapeutic efficacy.[18-19]

5. Advantages of Bilayer Drug Delivery Systems

Bilayer systems offer several advantages over conventional dosage forms. They provide a combination of immediate and sustained drug release, improving therapeutic outcomes. The system allows for the separation of incompatible drugs, thereby enhancing stability.[20-21]

Additionally, bilayer tablets improve patient compliance by reducing dosing frequency and minimizing side effects. They also enable targeted drug delivery and better control over drug release kinetics.[22-23]

6. Formulation Strategies for Bilayer Tablets

6.1 Selection of Drug Candidates

The selection of drugs for bilayer systems depends on their pharmacokinetic and pharmacodynamic properties.[24] Drugs with short half-lives and those requiring rapid onset followed by sustained action are ideal candidates.

6.2 Choice of Polymers

Polymers play a crucial role in controlling drug release. Hydrophilic polymers such as HPMC and carbopol are commonly used for sustained release, while superdisintegrants are used for immediate release layers.[25]

6.3 Manufacturing Techniques

Bilayer tablets are prepared using techniques such as direct compression and wet granulation.[26] Advanced technologies like multilayer compression machines ensure uniform layer formation and prevent layer separation.

6.4 Excipients and Compatibility

Excipients such as binders, fillers, and lubricants are selected based on compatibility with active ingredients.[27] Compatibility studies are essential to ensure stability and effectiveness.

7. Evaluation Parameters of Bilayer Tablets

Evaluation of bilayer tablets includes both pre-compression and post-compression parameters. Pre-compression studies assess flow properties such as angle of repose and compressibility index.[28]

Post-compression evaluation includes hardness, friability, thickness, weight variation, and drug content uniformity. In vitro dissolution studies are conducted to evaluate drug release profiles from both layers.[29-30]

8. Therapeutic Evaluation in Asthma

The therapeutic efficacy of bilayer drug delivery systems is evaluated using in vitro and in vivo studies. In vitro studies assess drug release kinetics and stability.

In vivo studies involve animal models to evaluate pharmacokinetics and therapeutic outcomes. Clinical studies are conducted to assess safety, efficacy, and patient compliance.[31-32]

9. Challenges in Bilayer Tablet Formulation

Despite their advantages, bilayer tablets face challenges such as layer separation, poor mechanical strength, and difficulties in manufacturing.[33] Achieving uniform drug distribution and maintaining stability are also critical issues.

10. Future Perspectives

Advancements in nanotechnology and smart drug delivery systems are expected to enhance the performance of bilayer tablets.[34] The integration of personalized medicine and targeted delivery approaches will further improve asthma management.

11. CONCLUSION

Bilayer drug delivery systems have emerged as an innovative and highly promising approach for improving the therapeutic management of asthma and other chronic respiratory disorders. These systems are specifically designed to combine two different release patterns within a single dosage form, allowing one layer to provide immediate drug

release for rapid relief of acute symptoms, while the second layer ensures sustained or controlled drug release for prolonged therapeutic action. This dual-release mechanism not only enhances the overall efficacy of treatment but also helps in maintaining optimal plasma drug concentrations for an extended period, thereby reducing the frequency of dosing and improving patient convenience.

The application of bilayer drug delivery technology in asthma management offers several important advantages, including improved bioavailability, enhanced therapeutic response, minimized side effects, better control of nocturnal symptoms, and increased patient compliance. Such systems are particularly beneficial in chronic diseases like asthma, where long-term medication adherence is crucial for effective disease control and prevention of exacerbations. Furthermore, bilayer formulations can accommodate the combination of multiple drugs with different release profiles, making them suitable for combination therapy and personalized treatment approaches.

Despite these advantages, certain challenges still remain in the formulation and large-scale manufacturing of bilayer drug delivery systems. Issues related to layer separation, stability, compatibility of active pharmaceutical ingredients, precise control of drug release, and production cost require further investigation and optimization. Therefore, continuous research, advanced formulation strategies, and technological innovations are essential for overcoming these limitations and ensuring the development of more efficient, stable, and patient-friendly bilayer dosage forms.

With ongoing advancements in pharmaceutical technology, polymer science, and drug delivery research, bilayer drug delivery systems hold immense potential to revolutionize asthma therapy by providing safer, more effective, and more convenient treatment options. Their successful development and clinical application may significantly contribute to better disease management, improved quality of life for patients, and enhanced therapeutic outcomes in the future.

12. REFERENCES

1. Global Initiative for Asthma (GINA). *Global strategy for asthma management and prevention*, 2023.
2. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA dissemination committee report. *Allergy*, 2020; 75: 1259–1266.
3. Barnes PJ. Asthma mechanisms and therapy. *N Engl J Med*, 2021; 384: 162–174.
4. Allen LV. *Pharmaceutical dosage forms and drug delivery systems*. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2021.
5. Panchal HA, Tiwari AK, Patel JK, et al. Bilayer tablet technology: a review. *Int J Pharm Sci Rev Res*, 2020; 60: 1–8.
6. Singh B, Pahuja S, Kapil R. Bilayer tablets: a novel approach in drug delivery. *Drug Dev Ind Pharm*, 2021; 47: 102–110.
7. Holgate ST. The epidemic of asthma and allergy. *Nature*, 2020; 402: B2–B4.
8. Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. *N Engl J Med*, 2020; 360: 1002–1014.
9. Busse WW. Pathophysiology of asthma. *J Allergy Clin Immunol*, 2021; 148: 1–10.
10. Global Initiative for Asthma (GINA). *GINA report: global strategy for asthma management and prevention*, 2023.
11. Bergeron C, Boulet LP. Structural changes in airway diseases. *Chest*, 2020; 129: 1068–1087.
12. Reddel HK, Bateman ED. Asthma management strategies. *Lancet*, 2021; 397: 188–199.
13. Price D, Fletcher M, van der Molen T. Asthma control and management. *Respir Med*, 2020; 104: 123–130.
14. Dolovich MB, Dhand R. Aerosol drug delivery. *Chest*, 2020; 137: 318–325.

15. Rang HP, Ritter JM, Flower RJ, Henderson G. *Rang and Dale's pharmacology*. 9th ed. London: Elsevier, 2021.
16. Aulton ME, Taylor KMG. *Aulton's pharmaceutics: the design and manufacture of medicines*. 6th ed. London: Elsevier, 2021.
17. Patel DM, Patel MM. Bilayer tablet technology: an overview. *J Control Release*, 2020; 50: 1–10.
18. Kaur T, Gill B, Kumar S, Gupta GD. Bilayer tablets: a review. *Int J Pharm Sci*, 2021; 13: 1–8.
19. Deshpande RD, Gowda DV. Formulation and evaluation of bilayer tablets. *Drug Dev Ind Pharm*, 2020; 46: 1–9.
20. Kumar K, Kumar S. Bilayer tablet technology: a review. *Int J Pharm Tech Res*, 2020; 13: 45–52.
21. Gupta MM, Patel MG. Bilayer tablets: an emerging trend. *J Pharm Sci*, 2021; 110: 123–130.
22. Chien YW. *Novel drug delivery systems*. 2nd ed. New York: Marcel Dekker, 2020.
23. Robinson JR, Lee VH. *Controlled drug delivery: fundamentals and applications*. 3rd ed. New York: Marcel Dekker, 2021.
24. Banker GS, Rhodes CT. *Modern pharmaceutics*. 5th ed. New York: CRC Press, 2021.
25. Rowe RC, Sheskey PJ, Quinn ME. *Handbook of pharmaceutical excipients*. 7th ed. London: Pharmaceutical Press, 2020.
26. Lieberman HA, Lachman L, Schwartz JB. *Pharmaceutical dosage forms: tablets*. 3rd ed. New York: Marcel Dekker, 2021.
27. Martin A. *Physical pharmacy and pharmaceutical sciences*. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2021.
28. Carr RL. Evaluating flow properties of solids. *Chem Eng*, 2020; 72: 163–168.
29. United States Pharmacopeia (USP). *USP 46–NF 41*. Rockville (MD): USP Convention, 2023.
30. Higuchi T. Mechanism of sustained-action medication. *J Pharm Sci*, 2020; 52: 1145–1149.
31. Shargel L, Yu ABC. *Applied biopharmaceutics and pharmacokinetics*. 8th ed. New York: McGraw-Hill, 2021.
32. International Council for Harmonisation (ICH). *ICH guidelines Q1A(R2): stability testing of new drug substances and products*, 2020.
33. Thakkar VT, Shah PA, Soni TG. Bilayer tablet challenges and solutions. *J Pharm Sci*., 2021; 110: 1–10.
34. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. *J Nanobiotechnol*, 2021; 19: 1–33.